Table 4. Correlations between PRLR expression and clinicopathological parameters.
|
PRLR immunoreactivity
|
|||
|---|---|---|---|
| Clinicopathological variables | PRLR low expression | PRLR high expression | P-value |
| T classification | |||
| T1 | 2 (25%) | 35 (43%) | 0.511 |
| T2 | 3 (37.5%) | 18 (22%) | |
| T3 | 1 (12.5%) | 9 (11) | |
| T4 | 2 (25%) | 19 (24%) | |
| N classification | |||
| N0 | 7 (87.5%) | 53 (65%) | 0.195 |
| N1–3 | 1 (12.5%) | 28 (35%) | |
| Tumour grade | |||
| G1 | 3 (37.5%) | 15 (19%) | 0.404 |
| G2 | 3 (37.5%) | 43 (53%) | |
| G3 | 2 (25%) | 23 (28%) | |
| Stage | |||
| I | 2 (37.5%) | 32 (40%) | 0.868 |
| II | 3 (37.5%) | 13 (16%) | |
| III | 1 (12%) | 11 (14%) | |
| IV | 2 (25%) | 25 (31%) | |
| Gender | |||
| M | 5 (62%) | 62 (76%) | 0.310 |
| F | 3 (38%) | 19 (24%) | |
| Age | |||
| <60 | 4 (50%) | 44 (54%) | 0.551 |
| >60 | 4 (50%) | 37 (45%) | |
Abbreviation: PRLR=prolactin receptor.